(Total Views: 421)
Posted On: 12/15/2017 7:50:00 PM
Post# of 30066
Re: jamiejaytrader #25627
Speaking of ESS, it was Dr. Joe that brought the opportunity to the company. It was tied up in over a billion dollar lawsuit and he stepped in along with AMBS to settle it. I guess he could have done it being on the BOD of Regenicin or even started his own company and done it.
Why did he do what he did? One (me) would believe Dr. Joe saw the potential of Amarantus with MANF as being one of the first regenerative medicine companies.
You can see how his relationship with Amarantus and Dr. John Commisiong developed over the years from advisor to BOD to helping work out a deal of a product he believed in. Keep in mind it's not like Dr. Joe was sitting on 20 boards over the last 5 years and I'm sure 500 other companies would have loved his collaboration.
Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors
Aug 25, 2010
https://www.fiercebiotech.com/biotech/regenic...-directors
Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
NOVEMBER 06, 2012
https://www.amarantus.com/news/press-releases...-dr-joseph
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors
December 08, 2014
http://globenewswire.com/news-release/2014/12...ml?print=1
Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns
JULY 15, 2015
https://www.amarantus.com/news/press-releases...za-for-the
Why did he do what he did? One (me) would believe Dr. Joe saw the potential of Amarantus with MANF as being one of the first regenerative medicine companies.
Quote:
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug ."
You can see how his relationship with Amarantus and Dr. John Commisiong developed over the years from advisor to BOD to helping work out a deal of a product he believed in. Keep in mind it's not like Dr. Joe was sitting on 20 boards over the last 5 years and I'm sure 500 other companies would have loved his collaboration.
Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors
Aug 25, 2010
https://www.fiercebiotech.com/biotech/regenic...-directors
Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
NOVEMBER 06, 2012
https://www.amarantus.com/news/press-releases...-dr-joseph
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors
December 08, 2014
http://globenewswire.com/news-release/2014/12...ml?print=1
Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns
JULY 15, 2015
https://www.amarantus.com/news/press-releases...za-for-the
(9)
(0)
